CEO Marc Casper says the company’s DynaDrive single-use bioreactor platform is becoming the “favored” technology for efficient, scalable bioproduction.
The agreement provides U.S. commercial and global clinical manufacturing capacity as Kyverna prepares regulatory filings and potential launches for CAR-T therapy.
The energy-efficient facility doubles the company’s production capacity for pharmaceutical glass packaging in China and includes room for future expansion.
